Page last updated: 2024-12-10

5-methoxycarbonylamino-n-acetyltryptamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-methoxycarbonylamino-N-acetyltryptamine: an mt1/MT2 receptor agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4284525
CHEMBL ID504585
CHEBI ID93457
SCHEMBL ID4655625
MeSH IDM0370172

Synonyms (36)

Synonym
HMS3266P16
BRD-K83023055-001-01-9
PDSP2_001790
PDSP1_001807
tocris-0896
NCGC00024854-01
5mca-nat
NCGC00024854-03
NCGC00024854-02
5-methoxycarbonylamino-n-acetyltryptamine
5-mca-nat
methyl 3-(2-acetamidoethyl)-1h-indol-5-ylcarbamate
bdbm50260394
CHEMBL504585 ,
methyl n-[3-(2-acetamidoethyl)-1h-indol-5-yl]carbamate
methyl {3-[2-(acetylamino)ethyl]-1h-indol-5-yl}carbamate
mzc ,
FT-0671182
gr 135531
190277-13-5
gtpl3393
MPZVHKLZCUEJFO-UHFFFAOYSA-N
SCHEMBL4655625
AKOS024458683
DTXSID70401560
gr-135531
J-001105
sr-01000597437
SR-01000597437-1
CHEBI:93457
J-012284
HMS3675D22
Q27073988
HMS3411D22
gr135531;gr 135531;5-mca-nat
carbamic acid, n-[3-[2-(acetylamino)ethyl]-1h-indol-5-yl]-, methyl ester
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency0.94660.531815.435837.6858AID504845
glucocerebrosidaseHomo sapiens (human)Potency8.91250.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency6.30960.035520.977089.1251AID504332
DNA polymerase kappa isoform 1Homo sapiens (human)Potency29.93490.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)IC50 (µMol)0.03940.00271.62879.9000AID396398; AID594258; AID594262
Metabotropic glutamate receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)2.50000.00020.58878.9900AID594256; AID594257
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)4.00000.00001.819410.0000AID382164
Melatonin receptor type 1AHomo sapiens (human)IC50 (µMol)0.55000.00000.06401.0200AID382163; AID594256
Melatonin receptor type 1BHomo sapiens (human)IC50 (µMol)4.00000.00000.34894.0000AID382164; AID594257
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
quinone catabolic processRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMelatonin receptor type 1AHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayMelatonin receptor type 1AHomo sapiens (human)
mating behaviorMelatonin receptor type 1AHomo sapiens (human)
circadian rhythmMelatonin receptor type 1AHomo sapiens (human)
G protein-coupled receptor signaling pathwayMelatonin receptor type 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMelatonin receptor type 1BHomo sapiens (human)
chemical synaptic transmissionMelatonin receptor type 1BHomo sapiens (human)
negative regulation of cGMP-mediated signalingMelatonin receptor type 1BHomo sapiens (human)
glucose homeostasisMelatonin receptor type 1BHomo sapiens (human)
camera-type eye developmentMelatonin receptor type 1BHomo sapiens (human)
negative regulation of neuron apoptotic processMelatonin receptor type 1BHomo sapiens (human)
negative regulation of vasoconstrictionMelatonin receptor type 1BHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, non-REM sleepMelatonin receptor type 1BHomo sapiens (human)
negative regulation of insulin secretionMelatonin receptor type 1BHomo sapiens (human)
regulation of insulin secretionMelatonin receptor type 1BHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationMelatonin receptor type 1BHomo sapiens (human)
negative regulation of transmission of nerve impulseMelatonin receptor type 1BHomo sapiens (human)
positive regulation of transmission of nerve impulseMelatonin receptor type 1BHomo sapiens (human)
regulation of neuronal action potentialMelatonin receptor type 1BHomo sapiens (human)
G protein-coupled receptor signaling pathwayMelatonin receptor type 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
dihydronicotinamide riboside quinone reductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
zinc ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
electron transfer activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activity, acting on other nitrogenous compounds as donorsRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
chloride ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein homodimerization activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
FAD bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
melatonin bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
resveratrol bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
NAD(P)H dehydrogenase (quinone) activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein bindingMelatonin receptor type 1AHomo sapiens (human)
melatonin receptor activityMelatonin receptor type 1AHomo sapiens (human)
hormone bindingMelatonin receptor type 1AHomo sapiens (human)
organic cyclic compound bindingMelatonin receptor type 1AHomo sapiens (human)
G protein-coupled receptor activityMelatonin receptor type 1AHomo sapiens (human)
protein bindingMelatonin receptor type 1BHomo sapiens (human)
melatonin receptor activityMelatonin receptor type 1BHomo sapiens (human)
G protein-coupled receptor activityMelatonin receptor type 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
nucleoplasmRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
extracellular exosomeRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneMelatonin receptor type 1AHomo sapiens (human)
receptor complexMelatonin receptor type 1AHomo sapiens (human)
plasma membraneMelatonin receptor type 1AHomo sapiens (human)
plasma membraneMelatonin receptor type 1BHomo sapiens (human)
synapseMelatonin receptor type 1BHomo sapiens (human)
plasma membraneMelatonin receptor type 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID594259Selectivity ratio of IC50 for human MT1 to IC50 for human MT32011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.
AID594260Selectivity ratio of IC50 for human MT2 to IC50 for human MT32011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.
AID594256Binding affinity to human MT1 receptor2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.
AID1487621Inhibition of MT-3 (unknown origin)2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Oxindole-based intraocular pressure reducing agents.
AID1487622Binding affinity to MT-3 (unknown origin)2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Oxindole-based intraocular pressure reducing agents.
AID594257Binding affinity to human MT2 receptor2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.
AID396398Displacement of [125I]iodomelatonin from MT3/QR2 melatonin binding site expressed in CHO cells2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
A novel quantitative structure-activity relationship method to predict the affinities of MT3 melatonin binding site.
AID382164Displacement of 2-[125I]iodomelatonin from human MT2 receptor expressed in HEK293 cells2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3.
AID382414Selectivity ratio, IC50 for human MT1 melatonin receptor to IC50 for hamster MT3 melatonin binding site2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3.
AID594258Binding affinity to human low affinity melatonin (MT3) site of quinone reductase 22011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.
AID382167Selectivity ratio, IC50 for human MT2 melatonin receptor to IC50 for hamster MT3 melatonin binding site2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3.
AID1487629Reduction in intraocular pressure in New Zealand white rabbit at 100 mg/10 ml dosed via topical route measured after 0.5 to 6 hrs post dose by tonometry2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Oxindole-based intraocular pressure reducing agents.
AID382165Inhibition of MT3 melatonin binding site from hamster brain membrane2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3.
AID594262Binding affinity to low affinity melatonin (MT3) site of quinone reductase 22011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.
AID382163Displacement of 2-[125I]iodomelatonin from human MT1 receptor expressed in HEK293 cells2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (44.83)29.6817
2010's14 (48.28)24.3611
2020's2 (6.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.23 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index5.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]